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LESSONS LEARNED
• A phase I study of the pan-class I phosphoinositide 3-kinase inhibitor pilaralisib (in capsule formulation) in advanced solid
tumors established the maximum tolerated dose as 600 mg once daily.
• The current study investigated pilaralisib in tablet formulation.
• Pilaralisib tablets were associated with a favorable safety profile and preliminary antitumor activity.
• Based on pharmacokinetic data, the recommended phase II dose of pilaralisib tablets was established as 400 mg once daily.
ABSTRACT
Background. A phase I trial of pilaralisib, an oral pan-class I
phosphoinositide 3-kinase (PI3K) inhibitor, established the max-
imum tolerated dose (MTD) of the capsule formulation in
patients with advanced solid tumors as 600 mg once daily. This
phase I study investigated pilaralisib in tablet formulation.
Materials and Methods. Patients with advanced solid tumors
received pilaralisib tablets (100–600 mg once daily). Primary
endpoints were MTD and safety; secondary and exploratory
endpoints included pharmacokinetics (PK), pharmacodynamics,
and efﬁcacy.
Results. Twenty-two patients were enrolled. No dose-limiting tox-
icities (DLTs) were reported. The most common treatment-related
adverse events were diarrhea (40.9%), fatigue (40.9%), decreased
appetite (22.7%), and hyperglycemia (22.7%). Pilaralisib plasma
exposure did not appear to increase dose-proportionally. Steady-
state exposure was higher with pilaralisib tablet formulation at
400mg than with pilaralisib capsule formulation at 400 or 600mg
(mean area under the curve [AUC0–24] 2,820,000 ng 3 h/mL vs.
2,653,000 and 1,930,000 ng 3 h/mL, respectively). Of 18 evalu-
able patients, 2 (11.1%) had a partial response (PR).
Conclusion. Pilaralisib tablets were associated with a favorable
safety proﬁle and preliminary antitumor activity. MTD was not
determined. The recommended phase II dose for pilaralisib
tablets, based on PK data, was 400 mg once daily. The Oncolo-
gist 2018;23:401–e38
DISCUSSION
The PI3K pathway has been implicated in the pathogenesis of
solid tumors, and several PI3K inhibitors in development have
shown evidence of clinical antitumor activity. Pilaralisib
(SAR245408) is a highly selective and reversible pan-class I PI3K
inhibitor. A phase I study of pilaralisib capsules in 69 patients
with advanced solid tumors (NCT00486135) established the
MTD as 600 mg once daily. In addition, pharmacodynamic inhi-
bition of the PI3K pathway and one PR were observed. The cur-
rent study investigated pilaralisib in tablet formulation.
Twenty-two patients were enrolled and received at least
one dose of pilaralisib tablets. The median duration of exposure
was 56.0 days. No DLTs were observed, and the MTD was not
established. Safety ﬁndings with pilaralisib tablets were gener-
ally consistent with previous ﬁndings in patients with solid
tumors who received the capsule formulation. The most com-
mon treatment-related toxicities included gastrointestinal tox-
icities, fatigue, and hyperglycemia (Table 1), consistent with
other PI3K inhibitors in clinical development.
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Clinical Trial Results
In PK analyses, pilaralisib plasma exposure did not appear
to increase in a dose-proportional manner and steady-state
plasma exposure appeared to be slightly higher with pilaralisib
400 mg tablets compared with capsules at 400 mg and 600 mg
once daily (Fig. 1); however, small patient numbers prevented
ﬁrm conclusions. Pharmacodynamic impact on glucose homeo-
stasis was evaluated in plasma samples from patients receiving
pilaralisib tablets at 250, 400, and 600 mg (n5 2, n5 3, and
n5 2, respectively); no impact was observed on C-peptide or
glucose levels in the limited sample set analyzed. Similarly, no
impact was observed on C-peptide or glucose levels in plasma
samples from ﬁve patients with lymphoma receiving 600 mg
pilaralisib capsules.
Of 18 evaluable patients, two patients (11.1%) had a PR
(overall response rate 11.1%) and six patients (33.3%) had sta-
ble disease as best response. Median progression-free survival
was 1.9 months (90% conﬁdence interval 1.7–5.5); three
patients (16.7%) were alive and progression free at 6 months.
Based on PK data, the recommended phase II dose of pilar-
alisib tablets was established as 400 mg once daily.
Table 1. Treatment-related adverse events occurring in >5% of patients treated with pilaralisib tablets once daily (graded
according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0)
100 mg (n5 3) 200 mg (n5 6) 250 mg (n5 3) 400 mg (n5 7) 600 mg (n5 3) Total (n5 22)
Adverse events
Any
grade,
n (%)
Grade 3,
n (%)
Any
grade,
n (%)
Grade
3,
n (%)
Any
grade,
n (%)
Grade
3,
n (%)
Any
grade,
n (%)
Grade
3,
n (%)
Any
grade,
n (%)
Grade
3,
n (%)
Any
grade,
n (%)
Grade
3,
n (%)
Diarrhea 1 (33.3) 0 2 (33.3) 1 (16.7) 1 (33.3) 0 2 (28.6) 0 3 (100.0) 0 9 (40.9) 1 (4.5)
Fatigue 2 (66.7) 0 1 (16.7) 0 3 (100.0) 0 2 (28.6) 0 1 (33.3) 0 9 (40.9) 0
Decreased appetite 0 0 1 (16.7) 0 0 0 3 (42.9) 0 1 (33.3) 0 5 (22.7) 0
Hyperglycemia 1 (33.3) 0 1 (16.7) 0 1 (33.3) 0 1 (14.3) 0 1 (33.3) 0 5 (22.7) 0
Nausea 0 0 1 (16.7) 0 1 (33.3) 0 1 (14.3) 0 1 (33.3) 0 4 (18.2) 0
Rash 0 0 1 (16.7) 0 1 (33.3) 0 2 (28.6) 1 (14.3) 0 0 4 (18.2) 1 (4.5)
Amylase increased 1 (33.3) 1 (33.3) 1 (16.7) 0 0 0 0 0 0 0 2 (9.1) 1 (4.5)
Anemia 0 0 0 (0.0) 0 1 (33.3) 0 1 (14.3) 0 0 0 2 (9.1) 0
Dry skin 0 0 1 (16.7) 0 0 0 0 0 1 (33.3) 0 2 (9.1) 0
Hemoglobin
decreased
0 0 1 (16.7) 0 0 0 1 (14.3) 0 0 0 2 (9.1) 0
Rash, follicular 1 (33.3) 0 0 (0.0) 0 1 (33.3) 0 0 0 0 0 2 (9.1) 0
Rash, pustular 0 0 1 (16.7) 0 0 0 1 (14.3) 0 0 0 2 (9.1) 0
Figure 1. Mean (1 standard deviation [SD]) plasma concentration of pilaralisib administered once daily in patients with solid tumors on
Cycle 1, Day 1 (A), and Cycle 1 Day 28 (B). SD was not calculable for 100 mg and 250 mg tablets at Cycle 1, Day 1, for the 24-hour time
point or for 600 mg tablets at Cycle 1, Day 28 (n5 2 for each).
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TRIAL INFORMATION
Disease Advanced cancer/Solid tumor only
Stage of Disease/Treatment Metastatic/Advanced
Prior Therapy No designated number of regimens
Type of Study – 1 Phase I
Type of Study – 2 Null
Primary Endpoint Maximum tolerated dose
Primary Endpoint Toxicity
Secondary Endpoint Pharmacokinetics
Secondary Endpoint Pharmacodynamic
Secondary Endpoint Efﬁcacy
Additional Details of Endpoints or Study Design
This was a phase I, multicenter, open-label, single-arm study. The primary endpoints were MTD and safety. Secondary or
exploratory endpoints included pharmacokinetics, pharmacodynamics, and efﬁcacy. Eligible patients were aged 18 years, with
an Eastern Cooperative Oncology Group (ECOG) performance status 2 and histologically conﬁrmed metastatic or unresectable
solid tumors. Patients were required to have adequate organ and bone marrow function, fasting plasma glucose <160 mg/dL,
and hemoglobin A1c <8%. Patients who had previously received treatment with a PI3K inhibitor were excluded. All patients
provided written informed consent.
Panel for Copy Number Alterations in Squamous Non-Small Cell Lung Cancer
DNA was isolated from macrodissected, 5-micron, formalin-ﬁxed, parafﬁn-embedded tumor tissue sections enriched for 50%
tumor cell content, using standard protocols. DNA was analyzed by droplet digital polymerase chain reaction (ddPCR; BioRad,
Mountain View, CA) for copy number ampliﬁcations at the following 12 genic loci: BCL2, CCND1, CDK4, EGFR, ERBB2, FGFR1,
FGFR2, FGFR3, FGFR4, MET, PDGFRA, and PIK3CA. Two locus-speciﬁc TaqMan minor groove binder probes (ThermoFisher
Scientiﬁc, Waltham, MA) were used to measure the concentration of target-speciﬁc gene sequences relative to the concentration
of reference loci. Quantiﬁcation of these concentrations provided a ratio of the target to reference loci and was expressed as an
absolute copy number. To minimize aneusomy at the reference loci, the reference locus (RPP30, c.16_c.77, chr10q23) was
interrogated against two additional reference loci (AP3B1, c.2578–23605_c.2578_23543, chr5q14; NFAT5, c.327_c.395, chr16q22)
such that each target locus was normalized to the average concentration of the three reference loci.
Whole-Exome Sequencing
Whole-exome sequencing was performed as previously described [Nat Med 2014;20:682–688].
PTEN Immunohistochemistry
Immunohistochemistry for PTEN was performed using clone 138G6 (Cell Signaling Technology, Danvers, MA) within a Clinical
Laboratory Improvement Amendments-certiﬁed immunohistochemistry lab. PTEN loss was deﬁned as <10% tumor cells staining
at any intensity [PLoS One 2012; 7:e30427].
Investigator’s Analysis Drug tolerable, hints of efﬁcacy
DRUG INFORMATION FOR PHASE I PILARALISIB
Drug 1
Generic/Working Name Pilaralisib
Drug Type Small molecule
Drug Class PI3 kinase
Dose 100–600 mg (tablets) per day
Route Oral (p.o.)
Schedule of Administration Once daily, continuous 28-day cycles
PATIENT CHARACTERISTICS FOR PHASE I PILARALISIB
Number of Patients, Male 8
Number of Patients, Female 14
Stage Stage II — 1
Stage III — 2
Stage IIIA — 2
Stave IV — 9
Unknown stage — 8
Age Median (range), years: 63.0 (27–86)
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Number of Prior Systemic Therapies Median (range): 3.0 (0–12)
0–1 prior systemic therapies — 2 patients
2–4 prior systemic therapies — 14 patients
5 prior systemic therapies — 6 patients
Performance Status: ECOG 0 — 10
1 — 12
2 —
3 —
Unknown —
Other
Median Time from Initial Diagnosis Years (range): 2.63 (0.8–14.2)
Patients with Prior Anticancer Treatment Prior systemic anticancer therapy alone — 11
Prior radiation therapy alone — 1
Prior systemic anticancer therapy or radiation — 22
Both prior systemic anticancer therapy and
radiation — 10
CANCER TYPES OR HISTOLOGIC SUBTYPES
Adenocarcinoma 6
Bladder cancer 1
Carcinosarcoma 1
Chordoma (pelvis) 1
Colorectal adenocarcinoma 1
Ductal with lobular component (breast) 1
Endometrial cancer 3
Leiomyosarcoma (uterus) 1
Mesothelioma 2
Non-small cell lung cancer 2
Ovarian carcinoma 1
Prostate cancer 1
Sarcoma (synovial) 1
PRIMARYASSESSMENT METHOD FOR PHASE I PILARALISIB
Number of Patients Enrolled 22
Number of Patients Evaluable for Toxicity 22
Number of Patients Evaluated for Efﬁcacy 18
Evaluation Method RECIST 1.0
Response Assessment CR 0%
Response Assessment PR 11.1%
Response Assessment SD 33.3%
Response Assessment PD 55.6%
(Median) Duration Assessments PFS 1.9 months; CI, 1.7–5.5
(Median) Duration Assessments Duration of Treatment 56.0 days
ASSESSMENT, ANALYSIS, AND DISCUSSION
Completion Study completed
Investigator’s Assessment Drug tolerable, hints of efﬁcacy
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The phosphoinositide 3-kinase (PI3K) pathway is pivotal in
the growth and survival of normal cells, and dysregulation of
this pathway has been implicated in the pathogenesis of vari-
ous solid tumors [1–3]. Several PI3K inhibitors in development
have shown antitumor activity in patients with advanced solid
tumors [4–6].
Pilaralisib is a highly selective and reversible pan-class I
PI3K inhibitor. This single-arm study was part of a multicenter,
open-label, phase I study (NCT00486135), investigating single-
agent pilaralisib capsules in patients with advanced solid
tumors, which established the maximum tolerated dose
(MTD) for the capsule formulation at 600 mg once daily (QD)
[5]. Pharmacodynamic analyses demonstrated that pilaralisib
treatment inhibited the PI3K pathway, and one patient with
advanced non-small cell lung cancer had a partial response
(PR). The cohort described in this report investigated a tablet
formulation of pilaralisib. Primary endpoints were MTD and
safety. Secondary and exploratory endpoints included phar-
macokinetics (PK), pharmacodynamics and efﬁcacy.
In total, 22 patients with solid tumors received pilaralisib
tablets QD at 100 mg (n5 3), 200 mg (n5 6), 250 mg (n5 3),
400 mg (n5 7), or 600 mg (n5 3). Median age was 63.0 years
(range 27–86), and median number of prior systemic therapies
was 3 (range 0–12). All 22 patients discontinued study treat-
ment. The most common reasons for study discontinuation
were disease progression as deﬁned by RECIST version 1.0 (15
patients, 68.2%), disease progression based on clinical deterio-
ration (three patients, 13.6%), and adverse event (AE; two
patients, 9.1%). One patient was enrolled into an extension
study (TED12414).
The mean (6 standard deviation) duration of exposure was
158.0 days (6258.97 days) and ranged from 6 to 1,009 days.
Median duration of exposure was 56.0 days. Median number of
cycles received was 2 (range 1–36). The majority of patients
(90.9%) received>90% of the planned doses of pilaralisib.
No dose-limiting toxicities were reported. Treatment-
related grade 3 AEs reported were increased alanine ami-
notransferase, increased amylase, increased aspartate ami-
notransferase, diarrhea, increased gamma-glutamyl
transferase, increased lipase, and rash (one patient each, all
grade 3). Hepatic toxicity was reported in six patients
(27.3%) and was grade 3 in four patients (18.2%). There
were no events of bilirubin increased and no cases of Hy’s
law. There was no evidence of cardiovascular toxicity as
determined in ECG assessments. Seven patients (31.8%)
reported one or more serious AEs (SAEs), of which only dis-
ease progression (three patients, 13.6%) was reported in
more than one patient. All SAEs were assessed to be either
not related or unlikely to be related to treatment. Six
patients (27.3%) had one or more AEs leading to a dose
delay or interruption. Two patients (9.1%) permanently dis-
continued treatment because of an AE (grade 5 encephal-
opathy and grade 4 ischemic stroke); both AEs were not
treatment related. No deaths occurred during the study;
there were four deaths within 30 days after the last dose of
study drug, all related to disease progression.
Figure 1 shows the mean pilaralisib plasma concentration-
time proﬁle after the ﬁrst single dose on Cycle 1, Day 1, and
repeated daily dosing at Cycle 1, Day 28. After repeated
daily administration of pilaralisib tablets (100–600 mg),
steady state was reached by Cycle 1, Day 28, and median
time to maximum concentration ranged from 1.99 to 23.1
hours (Table 2). The mean accumulation ratio for maximum
concentration (Cmax) and area under the curve (AUC0–24)
for Cycle 1, Day 28, compared with Cycle 1, Day 1, ranged
from 5.9-fold to 10.3-fold and 3.1-fold to 9.9-fold, respec-
tively. Exposure (Cmax and AUC0–24) did not appear to
increase dose proportionally for the 100–600 mg dose lev-
els, but conclusions were limited by the small patient num-
bers. On Cycle 1, Day 28, exposure was higher with
pilaralisib 400 mg tablets administered QD compared with
600 mg tablets QD and the capsule formulation adminis-
tered at 400 mg and 600 mg QD (mean AUC0–24 2,820,000
[n5 2] vs. AUC0–24 1,470,000 [n5 2], 2,653,000 [n5 2] and
1,930,000 ng3 h/mL [n5 14], respectively).
The impact of pilaralisib tablets on glucose homeostasis
was evaluated in post-dose plasma samples after overnight
fasting (up to 2 hours after dosing) on Days 1, 8, and 28.
Pilaralisib had no effect on glucose and C-peptide levels. No
differences were observed between the capsule and tablet
formulation.
Of 18 evaluable patients, two patients (11.1%) had a PR
(overall response rate 11.1%): a female patient aged 53 years
with poorly differentiated vaginal adenocarcinoma who had
progression-free survival (PFS) of 33.0 months (200 mg cohort;
Fig. 2), and a female patient aged 41 years with squamous cell
lung carcinoma who had PFS of 27.6 months (250 mg cohort).
A squamous lung cancer copy number panel performed on a
prior pneumonectomy specimen demonstrated PIK3CA ampliﬁ-
cation (copy number alteration 4.6; >4 considered ampliﬁed),
with weak focal staining for PTEN in tumor cells. Mutational
analysis on whole exome sequencing demonstrated TP53
P151H, KRAS T20M, and PIK3C2B R296Q. A supraclavicular
lymph node biopsy performed after progression was inad-
equate for genomic analyses, but tumor cells identiﬁed were
negative for PTEN staining. PIK3CA ampliﬁcation, coupled with
PTEN loss and PIK3C2B mutation [7], possibly caused PI3K
dependence that resulted in the clinical beneﬁt observed. The
patient had PR at 11.6 months, maintained for 16 months
(maximum reduction in tumor burden 50.3%). Six patients
(33.3%) had stable disease as best response. Median PFS was
1.9 months (90% conﬁdence interval 1.7–5.5); three patients
(16.7%) were alive and progression free at 6 months.
In summary, pilaralisib tablets were associated with a favor-
able safety proﬁle, similar to that observed in patients who
received the capsule formulation [5]. The most common
treatment-related toxicities included gastrointestinal toxicities,
fatigue, and hyperglycemia (Table 1), consistent with other PI3K
inhibitors in clinical development [4, 6, 8–11]. Steady-state
plasma exposure was higher with pilaralisib 400 mg tablets
than with 400 and 600 mg capsules [5]. Neither tablets nor cap-
sules affected glucose homeostasis [5]. Pilaralisib tablets
showed preliminary antitumor activity, including two PRs. The
MTD for pilaralisib tablets was not determined and the recom-
mended phase II dose, based on PK data, is 400 mg QD.
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FIGURES AND TABLES
Figure 2. Partial response in a patient aged 54 years with poorly differentiated vaginal adenocarcinoma treated with pilaralisib tablets
200 mg once daily. Sequential computed tomography scans of the abdomen show a 32% interval reduction of a left para-aortic soft tissue
mass in Cycle 8, compared with baseline. Overall tumor reduction was 21% in Cycle 8.
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Table 2. Pilaralisib pharmacokinetic parameters in patients with solid tumors. Mean 6 standard deviation (geometric
mean) [% coefﬁcient of variation]
Parameter
Pilaralisib tablets, once-daily dose
Pilaralisib capsules
600 mg once daily100 mg 200 mg 250 mg 400 mg 600 mg
Cycle 1, Day 1
n 3 6 3 5 3 21
Cmax, ng/mL 7,0506 4,870
(5,220) [69.1]
13,0006 6,500
(11,500) [50.1]
14,3006 4,300
(13,900) [30.0]
17,3006 13,900
(14,000) [80.1]
18,3006 11,100
(15,100) [60.6]
13,9006 10,800
(10,300) [77.9]
tmax,
a h 3.95
(2.00–4.00)
3.06
(2.00–25.22)
2.05
(2.00–8.00)
8.00
(2.00–24.05)
23.12
(2.00–24.00)
8.00
(2.00–24.00)
AUC0–24,
ng 3 h/mL
174,0006NC
(174,000) [NC]b
272,0006 147,000
(239,000) [54.1]
253,0006NC
(249,000) [NC]b
361,0006 276,000
(292,000) [76.6]c
515,0006NC
(511,000) [NC]b
251,0006 193,000
(184,000) [76.9]
Cycle 1, Day 28
n 3 6 3 3 2 14
Cmax, ng/mL 45,3006 14,800
(43,600) [32.6]
92,1006 38,100
(84,300) [41.4]
77,7006 9,430
(77,300) [12.1]
105,0006 36,600
(99,800) [34.9]
71,9006NC
(71,300) [NC]
87,2006 40,300
(75,800) [46.3]
tmax,
a h 2.00
(2.00–8.23)
1.99
(0.00–8.12)
2.05
(0.00–4.00)
2.02
(2.00–21.30)
4.00
(0.00–8.00)
4.00
(0.00–8.00)
AUC0–24,
ng 3 h/mL
988,0006
292,000
(957,000) [29.5]
2,110,0006
791,000
(1,960,000) [37.4]d
1,720,0006
105,000
(1,720,000) [6.1]
2,820,0006NC
(2,820,000) [NC]e
1,470,0006NC
(1,460,000) [NC]
1,930,0006
913,000
(1,670,000) [47.3]
Rac Cmax
(vs. Cycle 1,
Day 1)
10.36 8.4 8.56 6.1 5.96 2.5 8.06 4.3 7.36NC 10.56 4.3
Rac AUC0–24
(vs. Cycle 1,
Day 1)
6.66NCe 9.96 7.6d 7.16NCe 7.76NCe 3.16NCf 13.06 6.8
Ctrough, ng/mL 35,9006 8,630
(35,200) [24.0]
82,1006 39,300
(72,500) [47.8]
66,3006 12,700
(65,400) [19.1]
97,5006 33,200
(93,000) [34.0]
70,1006NC
(69,200) [NC]
70,1006NC
(69,200) [NC]
aMedian (range).
b
n5 2.
c
n5 4.
d
n5 5.
e
n5 2.
f
n5 1.
Abbreviations: AUC, area under the curve; Cmax, maximum concentration; Ctrough, trough concentration; NC, not calculated; Rac, accumulation
ratio; tmax, time to maximum concentration.
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